發(fā)布時(shí)間：2018-05-21 13:26

  本文選題：胰腺癌 + 腫瘤標(biāo)志物　； 參考：《中國免疫學(xué)雜志》2017年01期

【摘要】：目的:探討血清腫瘤標(biāo)志物聯(lián)合檢測對(duì)胰腺癌的診斷價(jià)值及相關(guān)性。方法:選取2013年1月至2016年5月我院胰腺癌患者146例,非胰腺癌患者128例和健康體檢者124例,放射免疫分析儀檢測各組血清CA19-9、CA242、CA50、CA125、CEA及TSGF水平,并進(jìn)行各組間比較。繪制受試工作特征曲線(ROC)分析各腫瘤標(biāo)志物在胰腺癌患者中的診斷價(jià)值,線性相關(guān)分析各腫瘤標(biāo)志物的相關(guān)性。應(yīng)用多元Logistic回歸模型分析胰腺癌的獨(dú)立危險(xiǎn)因素。結(jié)果:胰腺癌組血清CA19-9、CA242、CA50、CA125、CEA及TSGF水平明顯高于對(duì)照組和非胰腺癌組,差異有統(tǒng)計(jì)學(xué)意義(P0.05或P0.01)。Ⅳ期和Ⅲ期患者血清CA19-9、CA242、CA50、CA125及TSGF水平明顯高于Ⅰ期和Ⅱ期(P0.01),且Ⅳ期患者血清CA19-9、CA242、CA125及CEA水平明顯高于Ⅲ期(P0.01)。胰腺癌組血清CA19-9、CA242、CA50、CA125、CEA及TSGF的陽性率明顯高于對(duì)照組和非胰腺癌組(P0.01)。ROC曲線顯示,血清CA19-9的AUC高于其他單項(xiàng)指標(biāo),其最佳臨界值、靈敏度和特異度分別為114.5 U/ml、81.2%和79.3%。6項(xiàng)聯(lián)合檢測的診斷效能均優(yōu)于各單項(xiàng)檢測,其靈敏度和特異度分別為92.4%和76.5%。相關(guān)性分析顯示,血清CA19-9與CA242、CA50及CA125均呈正相關(guān)(r=0.703,P=0.005;r=0.572,P=0.024;r=0.439,P=0.036)。多元Logistic回歸分析顯示,吸煙、不正確的飲食習(xí)慣、糖尿病史、膽系疾病史及CA19-9、CA242、CEA進(jìn)入回歸模型,其OR值及95%CI分別為1.717(0.736~2.359)、2.865(2.217~3.685)、2.614(2.186~3.127)、3.527(2.842~4.377)、4.214(3.570~4.962)、2.315(2.114~2.539)、1.876(1.175~2.852)。結(jié)論:血清腫瘤標(biāo)志物聯(lián)合檢測有助于提高早期胰腺癌診斷的準(zhǔn)確性,吸煙、不正確的飲食習(xí)慣、糖尿病史、膽系疾病史及高水平的CA19-9、CA242、CEA是胰腺癌的獨(dú)立危險(xiǎn)因素。
[Abstract]:Objective: to investigate the diagnostic value and correlation of serum tumor markers in pancreatic cancer. Methods: from January 2013 to May 2016, 146 patients with pancreatic cancer, 128 patients with non-pancreatic cancer and 124 healthy controls were selected. Serum CA19-9, CA242CA50, CA125CEA and TSGF levels were measured by radioimmunoassay. The diagnostic value of each tumor marker in pancreatic cancer patients was analyzed by drawing the work characteristic curve of the subjects, and the correlation of each tumor marker was analyzed by linear correlation analysis. Multivariate Logistic regression model was used to analyze the independent risk factors of pancreatic cancer. Results: the serum levels of CEA and TSGF in patients with pancreatic cancer were significantly higher than those in control group and non-pancreatic cancer group. The serum levels of CA19-9, CA242CA50, CA50, CA125 and TSGF in patients with stage 鈪，

本文編號(hào)：1919377